posted
CV Therapeutics Inc. said after the markets closed on Tuesday that its angina drug Ranexa proved ineffective in a clinical trial of acute and long-term treatment of patients with acute coronary syndrome. Palo Alto-based CV (NASDAQ:CVTX - News) said, however, it believes the data could support expansion of Ranexa's approved uses to include the drug as a first choice treatment for angina.
It is now approved for the treatment of chronic angina in patients who aren't responding adequately to other drugs.
The company further said there was no adverse trend in death or arrhythmias in patients taking the drug.
Published March 6, 2007 by the Silicon Valley / San Jose Business Journal
went down 30% after that news. Should be a nice quick gain IMO today/tomorrow
-------------------- who says you cant trade stocks at 17!!? Posts: 288 | From: Wisconsin | Registered: Apr 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
